Sale of Equity Interests in Theravance Respiratory Company, LLS and Discontinued Operations - Summary of discontinued operations (Details) - USD ($) $ in Thousands		12 Months Ended
	Jul. 20, 2022	Dec. 31, 2022	Dec. 31, 2023	Feb. 29, 2020
Schedule of Equity Method Investments [Line Items]
Provision for income tax expense		$ (178,974)
Net income from discontinued operations		$ 964,956
9.5% Non-Recourse Notes Due 2035
Schedule of Equity Method Investments [Line Items]
Interest rate (as a percent)		9.50%		9.50%
9.0% Non-Recourse 2033 Notes
Schedule of Equity Method Investments [Line Items]
Interest rate (as a percent)			9.00%
TRC
Schedule of Equity Method Investments [Line Items]
Income from investments in TRC, LLC		$ 53,200
Disposed of by Sale | TRC | Royalty Pharma
Schedule of Equity Method Investments [Line Items]
Income from investments in TRC, LLC		53,237
Transaction-related legal expenses (prior to July 20, 2022)		(5,057)
Loss on extinguishment of debt		(24,022)
Net gain from sale of equity interests in TRC, LLC	$ 1,141,100	1,141,084
Provision for income tax expense		(178,974)
Net income from discontinued operations		964,956
Disposed of by Sale | TRC | Royalty Pharma | 9.5% Non-Recourse Notes Due 2035
Schedule of Equity Method Investments [Line Items]
Interest expense on 9.5% Non-recourse notes due 2035		$ (21,312)